The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer …
Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
SHI Ou, RA Soo - Drug design, development and therapy, 2015 - Taylor & Francis
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line
treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR …
treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
The discovery that mutations in the EGFR gene are present in up to 50% of patients with
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
[引用][C] Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon egfr …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang… - DOI: https://doi. org …, 2022 - europepmc.org
(1) Background: Afatinib has been approved for patients with non-small cell lung cancer
(NSCLC) carrying major uncommon epidermal growth factor receptor gene (EGFR) …
(NSCLC) carrying major uncommon epidermal growth factor receptor gene (EGFR) …
First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
Background Few studies have compared the efficacy of the irreversible epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR …
factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR …
P1. 34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC
SP Aix, K Park, EH Tan, K O'Byrne, L Zhang… - Journal of Thoracic …, 2016 - jto.org
Background The irreversible ErbB family blocker afatinib and the reversible EGFR TKI
gefitinib are approved for first-line treatment of advanced EGFRm+ NSCLC. This phase IIb …
gefitinib are approved for first-line treatment of advanced EGFRm+ NSCLC. This phase IIb …
Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon EGFR …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang, SY Lei, T Li… - Cancers, 2022 - mdpi.com
Simple Summary Afatinib has been approved for patients with lung cancer carrying
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
EGFR-mutated non-small-cell lung cancer (NSCLC) has long been a research focus in lung
cancer studies. Besides reversible tyrosine kinase inhibitors (TKIs), new-generation …
cancer studies. Besides reversible tyrosine kinase inhibitors (TKIs), new-generation …
[HTML][HTML] Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non–small-cell lung cancer: final results from SWOG …
SB Goldberg, MW Redman, R Lilenbaum… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
S Igawa, T Ono, M Kasajima, S Kusuhara… - Investigational New …, 2020 - Springer
Introduction Afatinib is used to treat patients with advanced non-small cell lung cancer
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …